Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Survival in patients initiating home parenteral support due to nonmalignant short bowel syndrome compared with background population

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Translation and cultural adaptation of the scored Patient-Generated Subjective Global Assessment (PG-SGA©)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Perioperative clinical management in relation to emergency surgery for perforated peptic ulcer: A nationwide questionnaire survey

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. HIV, TB, inflammation and other correlates of serum phosphate: A cross-sectional study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Drug use in patients with short bowel syndrome and intestinal failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Impact of stoma leakage in everyday life: data from the Ostomy Life Study 2019

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Survival has frequently been studied and reported in patients with long term intestinal failure (IF). However, studies comparing the survival and mortality rates with the background population are rare. This study compares the survival in an adult IF, non-malignant, short bowel syndrome (SBS) cohort with a control group and with age- and sex-specific background mortality rates.

DESIGN: Patients with SBS, defined by a small bowel length of 200 cm or less, due to non-malignant disease, were included and followed until death or censoring on 31 December 2017. Causes of deaths occurring during home parenteral support (HPS) were assessed by review of the charts. Each case was matched with ten controls from the background population according to year of HPS initiation, age, and sex, and their survival was compared. Furthermore, age- and sex-specific mortality rates of the background population were used to calculate the standardized mortality ratio (SMR) and excess mortality.

RESULTS: After five years, patients who initiated HPS had a relative survival of 76%. The SMR was 5.0 and the excess mortality was 50 per 1000 years. HPS-related deaths were assessed to account for 11% of deaths during HPS and occurred with an incidence of 10 per 1000 years. The excess mortality was as low as 15 per 1000 years in cases aged less than 40 years. Patients weaning off HPS had a mortality rate closer to that expected in the background population.

CONCLUSIONS: In adult patients with a non-malignant cause of SBS-IF, the excess mortality was 50 per 1000 years. However, HPS related deaths were rarely registered with an incidence of 10 HPS related deaths per 1000 HPS treatment years.

OriginalsprogEngelsk
TidsskriftClinical Nutrition ESPEN
Vol/bind50
Sider (fra-til)170-177
Antal sider8
ISSN2405-4577
DOI
StatusUdgivet - aug. 2022

Bibliografisk note

Copyright © 2022 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.

ID: 79703615